Multimerization of hiv-1 vif protein as a therapeutic target
CA 2442909 C · Owner: Thomas Jefferson University · Inventors: Pomerantz, Roger; Zhang, Hui; Yang, Bin
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
One approach to treating individuals infected with HIV-1 is to administer to such individuals compounds that directly interfere with and intervene in the machinery by which HIV-1 replicates itself within human cells. Although the specific role of HIV-1 viral protein Vif in the viral life cycle is not known the Vif gene is essential for the pathogenic replication of lentivirusesin vivo. The present invention relates to a method for treating an individual exposed to or infected with HIV-1. Individuals identified as being exposed to or infected by HIV-1 are administered a therapeutically effective amount of one or more compounds that inhibit or prevent replication of said HIV-1 by …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 8, 2002 and granted November 29, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 8, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 8, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.